Detection of serum Granulysin concentration in patients with fixed drug eruption
Main Article Content
Abstract
Fixed drug eruption (FDE) is a type of drug reaction that manifests in the skin and mucous membranes, especially recurring in the same location (fixed) or in a new location upon re-exposure to suspected medicine. The pathogenesis of FDE may involve TCD8+ cells and their toxic proteins, such as granulysin. This cross-sectional descriptive study aimed to determine granulysin serum levels by ELISA and analyze its correlation with associated clinical characteristics. The Mann-Whitney U test was used to compare mean and or median values between groups. The Spearman rank correlation test was used to assess correlation. The statistical significance was considered as p-value < 0.05. Results showed that a total of 41 patients (24 males, 17 females) with a median age of 49 years old (interquartile range: 28 - 61) and 41 healthy controls were enrolled in this study. The median value of the lesional area was 3% body surface area (interquartile range: 3 - 5%). The median value of the number of lesions was 4 (interquartile range: 3 - 6). The median value of serum concentration of granulysin was 334.1 pg/ml (interquartile range: 208.6 - 530.2 pg/ml) in FDE patients, not statistically higher than that in the healthy control group (median value: 331.9 pg/ml; interquartile range: 157.9 - 470.7 pg/ml). There was no correlation between the serum granulysin concentration and lesional area or the number of lesions.
Article Details
Keywords
Drug eruption, fixed drug eruption, granulysin, generalized bullous fixed drug eruption
References
2. Miah MA, Ahmed SS, Chowdhury SA, Begum F, Rahman SH. Fixed drug eruptions due to cotrimoxazole. Mymensingh Med J MMJ. 2008; 17(2 Suppl):S1-5.
3. Brahimi N, Routier E, Raison-Peyron N, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol EJD. 2010; 20(4): 461-464. doi:10.1684/ejd.2010.0980.
4. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998; 37(11):833-838. doi:10.1046/j.1365-4362.1998.00451.x.
5. Heng YK, Yew YW, Lim DSY, Lim YL. An update of fixed drug eruptions in Singapore. J Eur Acad Dermatol Venereol JEADV. 2015; 29(8):1539-1544. doi:10.1111/jdv.12919.
6. Tripathy R, Pattnaik KP, Dehury S, et al. Cutaneous adverse drug reactions with fixed-dose combinations: Special reference to self-medication and preventability. Indian J Pharmacol. 2018; 50(4):192-196. doi:10.4103/ijp.IJP_760_16.
7. Mizukawa Y, Shiohara T. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses. Clin Exp Dermatol. 2010; 35(5): 493-497. doi:10.1111/j.1365-2230.2009.03622.x.
8. Cho YT, Lin JW, Chen YC, et al. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol. 2014; 70(3):539-548. doi:10.1016/j.jaad.2013.11.015.
9. Vũ Thị Dung. Nghiên cứu đặc điểm lâm sàng, các yếu tố liên quan và căn nguyên của hồng ban cố định nhiễm sắc. Luận văn Thạc sỹ Y học. Trường Đại Học Hà Nội. 2013.
10. Dharamsi FM, Michener MD, Dharamsi JW. Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome. J Emerg Med. 2015; 48(5): 551-554. doi:10.1016/j.jemermed.2014.09.049.
11. Byrd RC, Mournighan KJ, Baca-Atlas M, Helton MR, Sun NZ, Siegel MB. Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep. 2018; 4(9): 953-955. doi:10.1016/j.jdcr.2018.07.013.
12. Ozkaya-Bayazit E, Akar U. Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol. 2001; 45(5): 712-717. doi:10.1067/mjd.2001.117854.
13. Li H, Wiederkehr M, Rao B k, et al. Peculiar unilateral fixed drug eruption of the breast. Int J Dermatol. 2002; 41(2): 96-98. doi:10.1046/j.1365-4362.2002.01405.x.
14. Krensky AM, Clayberger C. Biology and clinical relevance of granulysin. Tissue Antigens. 2009; 73(3): 193-198. doi:10.1111/j.1399-0039.2008.01218.x.
15. Ogawa K, Takamori Y, Suzuki K, et al. Granulysin in human serum as a marker of cell-mediated immunity. Eur J Immunol. 2003; 33(7): 1925-1933. doi:10.1002/eji.200323977.
16. Saito N, Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Prolonged elevation of serum granulysin in drug-induced hypersensitivity syndrome. Br J Dermatol. 2012; 167(2): 452-453. doi:10.1111/j.1365-2133.2012.10921.x.